GlassScriptPhysician profile
Mohammad Yaseen
NPI 1437151693
$1,219.76
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2021: $11.23 · 2022: $120 · 2023: $261 · 2024: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $219.16 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $213.39 | 2023-2024 | Linzess |
| Janssen Biotech, INC. | $179.19 | 2022-2024 | Stelara, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $133.53 | 2024 | Zeposia |
| Genzyme Corporation | $105.67 | 2023-2024 | |
| Pfizer INC. | $91.47 | 2019 | |
| Abbvie INC. | $87.56 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.76 | 2022-2023 | Entyvio |
| Qol Medical, LLC | $32.26 | 2024 | Sucraid |
| Ardelyx, INC. | $29.84 | 2023 | Ibsrela |
| Mirum Pharmaceuticals, INC. | $24.29 | 2023 | Livmarli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.29 | 2023 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $17.12 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $16.00 | 2024 | Dificid |
| Gilead Sciences, INC. | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Yaseen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.